Strategic partnerships Leverage existing alliance with Qiagen and ongoing collaboration potential to expand CDx development, manufacturing, and regulatory support for pharma clients seeking end-to-end companion diagnostics.

AML MRD expansion Capitalize on recent AML MRD CLIA-validated test launches to upsell additional ctDNA panels for hematologic malignancies and explore cross-selling into other MRD monitoring programs across oncology indications.

HNSCC and target niches Utilize the proven HNSCC sequencing service to pursue broader HPV-negative head and neck cancer programs and related mutation-driven indications with high unmet need and measurable MRD or response monitoring value.

Real-time actionable Highlight Plasma-Safe-SeqS and broad NGS coverage as capability advantages for real-time therapy selection and monitoring, presenting as a differentiator for biopharma sponsors aiming to optimize clinical trial outcomes.

Growth through services Offer scalable CLIA-certified lab services and rapid custom development programs to pharma clients seeking flexible assay development, regulatory-ready CDx components, and faster time-to-market for oncology therapeutics.